3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Oligodendroglioma
1
Gliosarcoma
1
Glioblastoma
1
Ependymoma
1
Astrocytoma
1
Interventions
Temozolomide
23
Radiotherapy
15
Radiation
7
Bevacizumab
6
temsirolimus
5
Sirolimus
5
Radiotherapy, Conformal
5
Erlotinib Hydrochloride
5
Carmustine
5
Carboplatin
5
Radiotherapy, Intensity-Modulated
4
Everolimus
4
Vorinostat
3
Irinotecan
3
veliparib
2
tipifarnib
2
plerixafor
2
pembrolizumab
2
atezolizumab
2
Surgical Procedures, Operative
2
Sorafenib
2
Gefitinib
2
Fluorodeoxyglucose F18
2
Cilengitide
2
Chemotherapy, Adjuvant
2
vatalanib
1
vandetanib
1
terameprocol
1
tandutinib
1
romidepsin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Gliosarcoma
×
picropodophyllin
×
Clear all
NCT01721577
2023-05-22
AXL1717
Rush University Medical Center
Phase 1/2
Terminated
10 enrolled
8 charts